https://platum.kr/archives/186160
Bioventure company RudaCure a obtenu a Series A investissement of KRW 6 billion.
RudaCure is primarily developing sécheresse oculaire and chronic traitement de la douleurs. The Series A round included Hanlim Pharmaceutical, Y&Archer Co., Ltd., and CKD Venture Capital as participating investisseurs.
The investisseurs stated that they decided to invest after highly evaluating the commercialization potential of RudaCure's traitement de la sécheresse oculaire 'RCI001,' recognizing its faster sécrétion lacrymale efficacy, récupération des lésions cornéennes capability, and superior instillation compliance and safety compared to commercially available competing drugs.
The traitement de la sécheresse oculaire market has been growing steadily due to the recent advancement of digital technology and the widespread adoption of vision correction procedures. RudaCure's 'RCI001' achieves rapid drug onset while significatifly reducing effets secondaires tels que élévation de la pression intraoculaire.
